Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

CHITOSAN HYDROCHLORIDE CRS (30 MG)

CHITOSAN HYDROCHLORIDE CRS (30 MG)

9012-76-4

DISCOVER
RUTOSIDE TRIHYDRATE CRS (100 MG)

RUTOSIDE TRIHYDRATE CRS (100 MG)

250249-75-3

DISCOVER
PILOCARPINE NITRATE FOR SYSTEM SUITABILITY CRS (20 MG)

PILOCARPINE NITRATE FOR SYSTEM SUITABILITY CRS (20 MG)

148-72-1

DISCOVER
TRIHEXYPHENIDYL HYDROCHLORIDECRS (80 MG)

TRIHEXYPHENIDYL HYDROCHLORIDECRS (80 MG)

52-49-3

DISCOVER
THIOMERSAL CRS (30 MG)

THIOMERSAL CRS (30 MG)

54-64-8

DISCOVER
ADIPIC ACID CRS (50 MG)

ADIPIC ACID CRS (50 MG)

124-04-9

DISCOVER
TRICHLOROACETIC ACID - REFERENCE SPECTRUM (N/A)

TRICHLOROACETIC ACID - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
LOBELINE HYDROCHLORIDE CRS (50 MG)

LOBELINE HYDROCHLORIDE CRS (50 MG)

134-63-4

DISCOVER
CARBACHOL CRS (50 MG)

CARBACHOL CRS (50 MG)

51-83-2

DISCOVER
SOTALOL HYDROCHLORIDE CRS (25MG)

SOTALOL HYDROCHLORIDE CRS (25MG)

959-24-0

DISCOVER
Sotalol impurity B CRS, 20mg

Sotalol impurity B CRS, 20mg

60735-85-5

DISCOVER
ACAMPROSATE IMPURITY A CRS (110 MG)

ACAMPROSATE IMPURITY A CRS (110 MG)

3687-18-1

DISCOVER